デフォルト表紙
市場調査レポート
商品コード
1451397

バイオロジクス市場レポート:由来、製品、疾患、製造、地域別、2024-2032

Biologics Market Report by Source, Product, Disease, Manufacturing, and Region 2024-2032

出版日: | 発行: IMARC | ページ情報: 英文 138 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.10円
バイオロジクス市場レポート:由来、製品、疾患、製造、地域別、2024-2032
出版日: 2024年03月02日
発行: IMARC
ページ情報: 英文 138 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のバイオロジクス市場規模は2023年に3,496億米ドルに達しました。今後、IMARC Groupは、2024年から2032年にかけて7.8%の成長率(CAGR)を示し、2032年には6,995億米ドルに達すると予測しています。より効果的な治療オプションが必要とされる慢性疾患の有病率の上昇、よりターゲットを絞った治療法の開発を促進する継続的な技術進歩、先進的ドラッグデリバリーシステムの出現は、市場を推進する要因のいくつかを表しています。

バイオロジクスは生きた細胞に由来する複雑な分子で、病気の診断、治療、予防に用いられます。これらの分子は、サイズだけでなくその構造の複雑さにおいても、低分子医薬品とは根本的に異なっています。高度な特異性を特徴とするこれらの医薬品は、細胞やタンパク質など、人体内の特定の成分と相互作用するように調整されています。このユニークな特性により、より正確に疾患経路をターゲットにすることができ、副作用を最小限に抑えながら、より高い有効性が期待できます。その作用機序は、生理的機能の回復や病的要因の除去のために、天然に存在する分子の活性を阻害または増強することにより、生物学的経路を調節することにあります。

このような複合分子の世界市場は、より効果的な治療法を必要とする慢性疾患の蔓延が主な要因となっています。これに伴い、継続的な技術の進歩により、標的を絞った治療法の市場開拓が促進され、市場に弾みがついています。さらに、ヘルスケア予算の拡大が先進的な治療オプションへの持続的な需要をもたらし、大きな成長促進要因となっています。これに加えて、個別化医療へのシフトがオーダーメイド治療の採用率向上につながり、市場をさらに拡大しています。市場の成長に寄与するその他の要因としては、情報に精通し教育された患者ベース、創薬における人工知能の最適化された役割、バイオ医薬品企業間の戦略的提携、特許切れ製剤がより多くの人々に利用されるようになったことによるバイオシミラーの出現などが挙げられます。

バイオロジクス市場の動向と促進要因:

標的治療における絶え間ないイノベーション

複合分子市場の重要な促進要因は、標的治療の絶え間ない革新です。これは、特定の細胞や疾患の原因分子に特異的に作用するように設計された治療法で、副作用を最小限に抑えながら治療効果を高めることができます。がんや自己免疫疾患のような疾患の重大な性質を考えると、標的療法は治療のための新規で効果的な手段を提供します。広範な科学的調査により、分子レベルでの疾病メカニズムの解明が可能になり、従来のアプローチよりも効果的で毒性の低い特殊な治療法への道が開かれました。研究開発への投資が増加し、個別化医療への注目度が高まるにつれて、こうした標的療法は主流になりつつあります。これらのイントロダクションの導入とその後の成功は、複合分子の需要を大幅に高める可能性があり、市場の極めて重要な促進要因となっています。

先進ドラッグデリバリーシステムの出現

ドラッグデリバリーシステムは、ヘルスケアにおいてますます重要な役割を果たすようになり、複雑な分子治療薬の有効性や患者のコンプライアンスを左右することも少なくないです。この分野における技術革新は、放出制御機構からナノテクノロジーに基づく送達システムまで、さまざまな形で現れています。このような進歩により、患者は治療レジメンを守りやすくなり、臨床転帰が改善されます。例えば、新しいデリバリー・システムは、毎日の注射を週1回、あるいは月1回の投与に置き換えることで、患者の利便性と治療継続意欲を大幅に向上させる可能性があります。複雑な分子の治療効果を最大化する目的で、こうした技術の研究開発には多額の投資が行われています。ドラッグデリバリーシステムにおけるこうした進歩は、より効率的で患者に優しい治療オプションへの需要を満たし、市場の回復力と成長性に大きく寄与しています。

規制の変化と調和

迷路のような規制環境の中を進むことは、ヘルスケア分野の企業にとって長い間困難な課題でした。しかし、規制調和に向けた現在の動向は、この複雑な状況を単純化しつつあります。異なる国間で統一された、あるいは相互に認められた承認プロセスにより、市場参入の障壁は大幅に軽減されます。つまり、新製品も既存製品も、以前よりずっと早く、より多くの患者層に届けられるようになるのです。革新的な治療薬が患者に提供されるペースが加速されるだけでなく、これらの製品の地理的範囲も大幅に拡大されます。承認の迅速化と市場アクセスの拡大による規制当局のこのような有利な連携は、複雑なバイオロジクス分子の世界市場の実質的かつ持続的な成長を促しています。

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 バイオロジクスの世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳:由来別

  • 微生物
    • 市場動向
    • 市場予測
  • 哺乳類
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 市場内訳:製品別

  • モノクローナル抗体
    • 市場動向
    • 市場予測
  • ワクチン
    • 市場動向
    • 市場予測
  • 組み換えタンパク質
    • 市場動向
    • 市場予測
  • アンチセンス、RNAi、分子療法
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第8章 市場内訳:疾患別

  • がん領域
    • 市場動向
    • 市場予測
  • 免疫疾患
    • 市場動向
    • 市場予測
  • 循環器疾患
    • 市場動向
    • 市場予測
  • 血液疾患
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 市場内訳:製造別

  • 製造委託
    • 市場動向
    • 市場予測
  • 社内
    • 市場動向
    • 市場予測

第10章 市場内訳:地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳:国別
    • 市場予測

第11章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • AbbVie Inc.
    • Amgen Inc.
    • AstraZeneca plc
    • F. Hoffmann-La Roche Ltd
    • GlaxoSmithKline plc
    • Johnson & Johnson
    • Merck KGaA
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
図表

List of Figures

  • Figure 1: Global: Biologics Market: Major Drivers and Challenges
  • Figure 2: Global: Biologics Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Biologics Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Biologics Market: Breakup by Source (in %), 2023
  • Figure 5: Global: Biologics Market: Breakup by Product (in %), 2023
  • Figure 6: Global: Biologics Market: Breakup by Disease (in %), 2023
  • Figure 7: Global: Biologics Market: Breakup by Manufacturing (in %), 2023
  • Figure 8: Global: Biologics Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Biologics (Microbial) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Biologics (Microbial) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Biologics (Mammalian) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Biologics (Mammalian) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Biologics (Other Sources) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Biologics (Other Sources) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Biologics (Monoclonal Antibodies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Biologics (Monoclonal Antibodies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Biologics (Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Biologics (Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Biologics (Recombinant Proteins) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Biologics (Recombinant Proteins) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Biologics (Antisense, RNAi and Molecular Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Biologics (Antisense, RNAi and Molecular Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Biologics (Other Products) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Biologics (Other Products) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Biologics (Oncology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Biologics (Oncology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Biologics (Immunological Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Biologics (Immunological Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Biologics (Cardiovascular Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Biologics (Cardiovascular Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Biologics (Hematological Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Biologics (Hematological Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Biologics (Other Diseases) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Biologics (Other Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Biologics (Outsourced) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Biologics (Outsourced) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Global: Biologics (In-House) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Global: Biologics (In-House) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: North America: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: North America: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: United States: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: United States: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Canada: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Canada: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Asia-Pacific: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Asia-Pacific: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: China: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: China: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Japan: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Japan: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: India: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: India: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: South Korea: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: South Korea: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Australia: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Australia: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Indonesia: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Indonesia: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Others: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Others: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Europe: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Europe: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Germany: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Germany: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: France: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: France: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: United Kingdom: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: United Kingdom: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Italy: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Italy: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Spain: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Spain: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Russia: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Russia: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Others: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Others: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Latin America: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Latin America: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Brazil: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Brazil: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Mexico: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Mexico: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Others: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Others: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 85: Middle East and Africa: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 86: Middle East and Africa: Biologics Market: Breakup by Country (in %), 2023
  • Figure 87: Middle East and Africa: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 88: Global: Biologics Industry: SWOT Analysis
  • Figure 89: Global: Biologics Industry: Value Chain Analysis
  • Figure 90: Global: Biologics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Biologics Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Biologics Market Forecast: Breakup by Source (in Million US$), 2024-2032
  • Table 3: Global: Biologics Market Forecast: Breakup by Product (in Million US$), 2024-2032
  • Table 4: Global: Biologics Market Forecast: Breakup by Disease (in Million US$), 2024-2032
  • Table 5: Global: Biologics Market Forecast: Breakup by Manufacturing (in Million US$), 2024-2032
  • Table 6: Global: Biologics Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Biologics Market: Competitive Structure
  • Table 8: Global: Biologics Market: Key Players
目次
Product Code: SR112024A3883

The global biologics market size reached US$ 349.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 699.5 Billion by 2032, exhibiting a growth rate (CAGR) of 7.8% during 2024-2032. The rising prevalence of chronic diseases that necessitate more effective treatment options, continual technological advancements facilitating the development of increasingly targeted therapies, and the emergence of advanced drug delivery systems represent some of the factors that are propelling the market.

Biologics are complex molecules derived from living cells, which are used to diagnose, treat, and prevent diseases. These molecules are fundamentally different from small-molecule drugs, not only in terms of size but also in the intricacy of their structure. Characterized by a high degree of specificity, these medicinal solutions are tailored to interact with specific components within the human body, such as cells and proteins. This unique attribute enables them to target disease pathways more precisely, offering a higher potential for efficacy while minimizing side effects. The working mechanism often involves the modulation of biological pathways, either by blocking or enhancing the activity of naturally occurring molecules, to restore physiological function or eliminate pathological agents.

The global market for these complex molecules is primarily driven by the rising prevalence of chronic diseases that necessitate more effective treatment options. In line with this, continual technological advancements facilitating the development of increasingly targeted therapies, which in turn is providing an impetus to the market. Moreover, expanding healthcare budgets are resulting in a sustained demand for advanced therapeutic options, acting as a significant growth-inducing factor. In addition to this, the shift toward personalized medicine is leading to higher adoption rates of tailored therapies, thus expanding the market further. Some of the other factors contributing to the market's growth include an informed and educated patient base, the optimizing role of artificial intelligence in drug discovery, strategic collaborations between biopharmaceutical entities, and the emergence of biosimilars as off-patent versions become more accessible to a larger population.

Biologics Market Trends/Drivers:

Continual innovations in targeted therapies

A significant driver in the market for complex molecules is the continuous innovation in targeted therapies. These are therapies designed to specifically act on certain cells or molecules responsible for disease, thus increasing treatment effectiveness while minimizing side effects. Given the critical nature of diseases like cancer and autoimmune disorders, targeted therapies offer a novel and effective avenue for treatment. Extensive scientific research has enabled the understanding of disease mechanisms at the molecular level, paving the way for specialized treatments that are more effective and less toxic than traditional approaches. With increasing investments in research and development, coupled with a heightened focus on personalized medicine, these targeted therapies are poised to become mainstream. Their introduction and subsequent success can substantially elevate the demand for complex molecules, thus serving as a pivotal driver for the market.

The emergence of advanced drug delivery systems

Drug delivery systems play an increasingly crucial role in healthcare, often determining the effectiveness and patient compliance for complex molecular treatments. Innovation in this sector comes in various forms, from controlled-release mechanisms to nanotechnology-based delivery systems. Such advancements make it easier for patients to adhere to their treatment regimens, thereby improving clinical outcomes. For instance, newer delivery systems might replace daily injections with weekly or even monthly doses, substantially enhancing patient convenience and willingness to continue treatment. Significant investments are flowing into the research and development of these technologies, with the aim to maximize the therapeutic effectiveness of complex molecules. These advances in drug delivery systems are contributing immensely to the market's resilience and growth potential, fulfilling a demand for more efficient and patient-friendly therapeutic options.

Regulatory changes and harmonization

Navigating through the labyrinthine regulatory environments has long been a daunting challenge for companies in the healthcare sector. However, the current trend toward regulatory harmonization is simplifying this complex landscape. With unified or mutually recognized approval processes across different countries, market entry barriers are substantially reduced. This means that new and existing products can reach a wider patient base much faster than before. The implications are manifold: not only is there an accelerated pace at which these innovative therapies are made available to patients, but there is also a significant expansion in the geographic reach of these products. This favorable alignment of regulatory practices, by expediting approvals and broadening market access, is driving substantial and sustained growth in the global market for complex biologics molecules.

Biologics Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global biologics market report, along with forecasts at the global, regional and country levels for 2024-2032. Our report has categorized the market based on source, product, disease, and manufacturing.

Breakup by Source:

Microbial

Mammalian

Others

Microbial accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the source. This includes microbial, mammalian, and others. According to the report, microbial represented the largest segment.

The microbial segment in the global market is mainly driven by its cost-effectiveness and shorter production times compared to mammalian cell cultures. The ability of microbial systems to produce large quantities of proteins makes them an attractive option for the mass production of vaccines and insulin. Moreover, advancements in microbial fermentation technologies are making it easier to produce complex proteins. Furthermore, a wide range of approved microbial-based products and a robust pipeline of microbial-based therapies are contributing to the growth of this segment.

On the other hand, the mammalian cell culture segment is particularly suited for the production of complex biologics that require post-translational modifications. Though costlier and more time-consuming than microbial systems, mammalian cell culture remains critical for certain high-value biologics, like monoclonal antibodies. Advances in cell line development and culture methods are contributing to increased yields and efficiency. Given the specific advantages, the mammalian segment continues to maintain a substantial share in the market.

Breakup by Product:

Monoclonal Antibodies

Vaccines

Recombinant Proteins

Antisense, RNAi and Molecular Therapy

Others

Monoclonal antibodies represents the largest market segment

The report has provided a detailed breakup and analysis of the market based on the product. This includes monoclonal antibodies, vaccines, recombinant proteins, antisense, RNAi and molecular therapy, and others. According to the report, monoclonal antibodies represented the largest segment.

The monoclonal antibodies (mAbs) segment is increasingly prominent due to their specificity in targeting a wide array of diseases including cancers, autoimmune disorders, and infections. Technological advancements in antibody engineering and hybridoma technologies have allowed for the development of highly specific and potent mAbs. Additionally, the growing number of FDA approvals for monoclonal antibodies further fuels this segment. The capacity for personalized treatment options using monoclonal antibodies also adds to its robust market potential.

On the other hand, the segments comprising vaccines, recombinant proteins, antisense RNAi, and molecular therapy, is primarily fueled by advances in genetic engineering and biotechnology. These approaches offer new avenues for treating a variety of diseases that are not adequately addressed by existing therapies. Investments in R&D are contributing to the growth of this segment, along with a growing understanding of the mechanisms behind these therapies. A robust pipeline of products in clinical trials indicates promising future prospects for these segments.

Breakup by Disease:

Oncology

Immunological Disorders

Cardiovascular Disorders

Hematological Disorders

Others

Oncology accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the disease. This includes oncology, immunological disorders, cardiovascular disorders, hematological disorders, and others. According to the report, oncology represented the largest segment.

The oncology segment in the global market is driven by the high prevalence of cancer worldwide and an aging population more susceptible to this disease. Advancements in genomics have facilitated the development of targeted therapies for various types of cancer. The growing awareness about personalized medicine and targeted therapy in cancer treatment is also propelling this segment forward. Moreover, a strong pipeline of oncology biologics in clinical trials indicates future market growth.

On the other hand, the minor segments consisting of immunological, cardiovascular, and hematological disorders is driven by increasing incidence rates and a lack of effective treatments in some cases. Emerging biologics offer novel methods for treating these conditions, including monoclonal antibodies and recombinant proteins. The growing awareness of these innovative treatments among healthcare professionals and patients is also contributing to these segments. A strong pipeline of therapies targeting these disorders is indicative of potential growth.

Breakup by Manufacturing:

Outsourced

In-House

In-house represents the largest market segment

The report has provided a detailed breakup and analysis of the market based on the manufacturing. This includes outsourced and in-house. According to the report, in-house represented the largest segment.

The in-house segment benefits from complete control over the research, development, and manufacturing processes. Organizations are increasingly preferring in-house production to protect intellectual property rights and proprietary technologies. In-house facilities also allow for quicker adaptations to market changes and more effective implementation of quality controls. The capacity for more integrated and streamlined operations contributes to the growth of the in-house segment in the global biologics market.

On the other hand, outsourcing is an increasingly common practice due to the high costs and complexities associated with biologics production. Organizations are utilizing contract manufacturing organizations (CMOs) to lower operational costs and accelerate time-to-market. Outsourcing also allows companies to focus on core competencies like R&D while leaving production to specialized firms. Thus, the outsourced segment is seeing consistent growth in the biologics market.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance, accounting for the largest biologics market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America dominates the global biologics market, primarily due to the presence of a well-established healthcare infrastructure and significant investments in biopharmaceutical research. The region is home to numerous leading biopharmaceutical companies and research institutions that drive innovation, which is creating a positive outlook for the market.

In addition to this, favorable regulatory support in the form of fast-track approvals for biologics and various financial incentives for extensive research and development (R&D) activities are also contributing to the market growth. Moreover, rising patient awareness and willingness to adopt new therapies are further fueling the demand for biologics in North America.

Furthermore, the U.S. is the largest market within the region, which is majorly buoyed by high healthcare spending, broad insurance coverage, and an increase in chronic and lifestyle-related diseases.

Competitive Landscape:

Key players in the global biologics market are aggressively focusing on innovation and research & development (R&D) activities. They are continually expanding their product pipelines to include advanced therapies in oncology, immunology, and other therapeutic areas. To meet stringent regulatory requirements, companies are investing significantly in state-of-the-art manufacturing facilities that adhere to good manufacturing practices. Collaborative agreements with academic institutions are being initiated for acquiring novel technologies. Through mergers and acquisitions, these organizations are consolidating their market presence. Strategic partnerships with smaller biotech companies are enabling the leveraging of unique skill sets and technologies. Furthermore, market leaders are engaging in patient access programs to facilitate the affordability of biologics.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

AbbVie Inc.

Amgen Inc.

AstraZeneca plc

F. Hoffmann-La Roche Ltd

GlaxoSmithKline plc

Johnson & Johnson

Merck KGaA

Novartis AG

Pfizer Inc.

Sanofi

Recent Developments:

In August 2023, AbbVie Inc. announced that the European Commission has approved AQUIPTA (atogepant) for the prophylaxis of migraine in adults who have four or more migraine days per month. The approval makes AQUIPTA the first and only once-daily oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) treatment in the European Union for the preventive treatment of both chronic and episodic migraine.

In September 2023, Amgen announced that it has reached a consent order agreement with the Federal Trade Commission, resolving a pending lawsuit and paving the way for its acquisition of Horizon Therapeutics. The companies anticipate finalizing the acquisition in early Q4 2023, focusing on serving patients with rare diseases.

In August 2023, AstraZeneca plc announced that Japan's Ministry of Health, Labour and Welfare has approved the expanded use of Soliris (eculizumab) for treating pediatric patients with generalized myasthenia gravis who are resistant to other therapies. The approval follows positive outcomes from a Phase III trial, making Soliris the first targeted therapy for this condition in children and adolescents in Japan.

Key Questions Answered in This Report

  • 1. What was the size of the global biologics market in 2023?
  • 2. What is the expected growth rate of the global biologics market during 2024-2032?
  • 3. What are the key factors driving the global biologics market?
  • 4. What has been the impact of COVID-19 on the global biologics market?
  • 5. What is the breakup of the global biologics market based on the source?
  • 6. What is the breakup of the global biologics market based on the product?
  • 7. What is the breakup of the global biologics market based on the disease?
  • 8. What is the breakup of the global biologics market based on the manufacturing?
  • 9. What are the key regions in the global biologics market?
  • 10. Who are the key players/companies in the global biologics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Biologics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Source

  • 6.1 Microbial
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Mammalian
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Others
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Product

  • 7.1 Monoclonal Antibodies
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Vaccines
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Recombinant Proteins
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Antisense, RNAi and Molecular Therapy
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Disease

  • 8.1 Oncology
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Immunological Disorders
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Cardiovascular Disorders
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Hematological Disorders
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by Manufacturing

  • 9.1 Outsourced
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 In-House
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 AbbVie Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Amgen Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 AstraZeneca plc
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 F. Hoffmann-La Roche Ltd
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 SWOT Analysis
    • 15.3.5 GlaxoSmithKline plc
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Johnson & Johnson
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Merck KGaA
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Novartis AG
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Pfizer Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Sanofi
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis